- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04170309
Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases (RETRACE)
Retrospective Chart Review to Evaluate the Safety Profile of Ceftobiprole in Patients With Impaired Hepatic or Renal Function or Immunosuppression
Study Overview
Status
Intervention / Treatment
Detailed Description
Rationale and background:
Ceftobiprole is a beta-lactam antibiotic with bactericidal activity against a broad spectrum of Gram-positive and Gram-negative bacteria, that was developed to treat patients with pneumonia both in a hospital or community setting. Clinical trials were conducted in adult immune-competent patients with normal or mild to moderate renal or hepatic function impairment. The clinical trial program completed to date has excluded patients with immune suppression and significant organ function impairment (hepatic or renal). The safety profile of ceftobiprole in these patient groups was recognized during the marketing authorization procedure as important missing information and the applicant committed to conduct a post authorization safety study.
A randomized Phase 3 study in the indication of acute bacterial skin and skin structure infections (ABSSSIs) is completed (NCT03137173), and a randomized Phase 3 study in the indication of S. aureus bacteremia is ongoing (NCT03138733). This retrospective chart review is conducted to further evaluate the safety profile of ceftobiprole in patient populations with specific risk factors.
Research question:
To estimate the proportion and the relative frequency of treatment-emergent adverse events (AEs) and adverse event of special interest will be assessed in patients treated with ceftobiprole and who have at least one of the following conditions:
- Impaired renal function
- Impaired hepatic function
- Immunosuppression
Treatment-emergent AEs are defined as events occurring after first study-drug administration, up to 28 days after the completion of treatment.
Adverse Events of Special Interest are the following;
- Hyponatraemia
- Hepatobiliary disorders
- Renal toxicity (including potential interactions with nephrotoxic drugs)
- Coombs test (DAT) positivity + clinical evidence of haemolysis
- Hypersensitivity reactions, including anaphylactic reactions
- Pseudomembranous colitis / C. difficile colitis
- Convulsions
The observed frequency of adverse events and adverse events of special interest in patients with the above risk factors will be compared to the frequency of these adverse events and adverse events of special interest in patients without these risk factors.
The study will enroll patients in whom treatment with ceftobiprole has been completed.
Patient charts will be selected from hospital sentinel sites.
Patient observation would normally be planned for 28 days after completion of ceftobiprole therapy. If, at the time of the review of any patient medical records, an AE has not been resolved, these patients would be followed up until resolution.
The study would continue until the target number of patients has been reached. The end date of this study would be set at the date of the last patient record review, or in cases where follow-up is extended beyond this period, until the end of follow-up.
Variables:
The following variables will be identified from the patient charts
- Year of birth and gender
- Weight
- Indication of treatment
- Attribution to a specific population group (see inclusion criteria) and criteria to assign the patient
- Start date of ceftobiprole
- Stop date of ceftobiprole and main reason for stopping (if known)
- Prescribed dose/regimen at treatment start
- Changes in dose during treatment
- Relevant medical history (diagnosis within 1 year prior to treatment start)
- Presence of ascites and hepatic encephalopathy at baseline
- Laboratory investigations undertaken as part of routine clinical practice and management of the patient related to the outcomes of interest, e.g., serum sodium, AST (aspartate aminotransferase), ALT (alanine aminotransferase), serum albumin, total bilirubin, GGT (gamma-glutamyltransferase) and AP (alkaline phosphatase), prothrombin time, INR (international normalized ratio), creatinine, haemoglobin, HCT (hematocrit), Coombs (DAT), C. difficile toxin tests prior (within 1 month) and up to 28 days after completion of treatment
- Findings of colonoscopy/sigmoidoscopy (for C. difficile colitis)
- Concomitant medication at baseline and up to 28 days after completion of treatment with focus on new onset use or dose modification of medications to treat hypersensitivity/anaphylaxis, convulsions, or C. difficile colitis
- Treatment-emergent AEs (event reports up to 28 days after completion of treatment), with focus on AEs of special interest (AESIs)
- Date and cause(s) of death (if applicable)
- Use during pregnancy (with follow-up until delivery)
Data sources:
This study will use data from patient charts, which includes physician and nurse notes, admission and discharge summaries, consultancy reports, laboratory test sheets, and microbiology sheets.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Shanti Amann, Dr.
- Phone Number: +4942167372154
- Email: info@ams-europe.com
Study Contact Backup
- Name: Noëlle Jemmely
- Phone Number: + 41 79 555 8269
- Email: Noelle.Jemmely@advanzpharma.com
Study Locations
-
-
-
Montpellier, France, 34295
- Montpellier Hopital Lapeyronie
-
Valenciennes, France, 34295
- Centre Hospitalier de Valenciennes
-
-
-
-
-
Neustadt/Harz, Germany, 99768
- Lungenklinik Neustadt GmbH
-
-
-
-
-
Bologna, Italy, 40138
- Ospedale Sant'Orsola Malpighi
-
Napoli, Italy, 80131
- AORN Ospedali dei Colli - Ospedale 'V. Monaldi
-
Napoli, Italy, 80131
- Policlinico Federico II
-
Perugia, Italy, 06129
- AO di Perugia -Ospedale Santa Maria della Misericordia
-
Pisa, Italy, 56124
- AOU Pisana-Cisanello
-
Pordenone, Italy
- AAS n 5 "Friuli Occidentale - Ospedale Santa Maria degli Angeli
-
Torino, Italy, 10126
- AOU Città della Salute e della Scienza Torino - Presidio Molinette
-
Varese, Italy
- ASST Settelaghi - Ospedale di Circolo e Fondazione Macchi
-
-
-
-
-
Barcelona, Spain, 08036
- Hospital Clínic de Barcelona, Clinical Research Infectious Disease Department (CRID)
-
Barcelona, Spain, 08221
- Hospital Universitari MútuaTerrassa Planta 15
-
Barcelona, Spain, 083035
- Servei de Malalties Infeccioses Hospital Universitari Vall D'Hebron
-
Granada, Spain, 18014
- Hospital Universitario Virgen de las Nieves, 4ª Planta Izquierda
-
Madrid, Spain, 28050
- Hospital La Moraleja
-
Madrid, Spain, 28047
- Hospital Central de la Defensa "Gomez Ulla" Planta 22
-
Valencia, Spain, 46026
- Hospital Universitario y Politécnico La Fe Servicio de Neumología. Torre E piso 4º
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
The study will enroll participants in whom treatment with ceftobiprole has been completed (including both on-label and off-label use) plus at least one of the following criteria (more than one criterion may apply):
- Participants with severe renal impairment / ESRD (end-stage renal disease, defined as calculated CLCr ( creatinine clearance) < 30 mL/minute or oliguria < 20 mL/hour unresponsive to fluid challenge or any form of dialysis)
- Impaired baseline hepatic function (patients with liver failure/cirrhosis Child Pugh Grade A, B, C or existing non-cirrhotic liver disease associated with total bilirubin > 2 mg/dL or alanine aminotransferase [ALT], or aspartate aminotransferase [AST] ≥ 3 times upper limit of the normal range [ULN])
Participants with immunosuppression, i.e.,
- HIV-positive with CD4 (cluster of differentiation 4) counts of ≤ 0.2 × 10E9/L (≤ 200 cells/mm3)
- Immunocompromised as determined by the investigator (any type or aetiology)
- Baseline neutropenia or baseline myelosuppression, defined as presence of myelosuppression or neutropenia (absolute neutrophil count [ANC] ≤ 0.5 × 10E9/L [< 500 polymorphonuclear neutrophils (PMNs)/mm3]), severe anaemia (haemoglobin < 6.5 g/dL), or severe thrombocytopenia (< 49.9 × 10E9/mm3) In addition, the study will enroll a control group of patients in whom treatment has been completed without any of the criteria listed above.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
With medical condition of interest
Participants treated with ceftobiprole with at least one of the following conditions:
|
Participants in whom treatment with Ceftobiprole medocaril has been completed
|
Without medical condition of interest
Patients treated with ceftobiprole without any of the following conditions:
|
Participants in whom treatment with Ceftobiprole medocaril has been completed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Estimation of the proportion and relative frequency of treatment-emergent AEs and AEs of special interest
Time Frame: during and until 28 days after completion of ceftobiprole therapy
|
during and until 28 days after completion of ceftobiprole therapy
|
Assessment of hyponatraemia
Time Frame: during and until 28 days after completion of ceftobiprole therapy
|
during and until 28 days after completion of ceftobiprole therapy
|
Assessment of hepatobiliary disorders
Time Frame: during and until 28 days after completion of ceftobiprole therapy
|
during and until 28 days after completion of ceftobiprole therapy
|
Assessment of renal toxicity (including potential interactions with nephrotoxic drugs)
Time Frame: during and until 28 days after completion of ceftobiprole therapy
|
during and until 28 days after completion of ceftobiprole therapy
|
Assessment of Coombs test (DAT) positivity + clinical evidence of haemolysis
Time Frame: during and until 28 days after completion of ceftobiprole therapy
|
during and until 28 days after completion of ceftobiprole therapy
|
Assessment of hypersensitivity reactions, including anaphylactic reactions
Time Frame: during and until 28 days after completion of ceftobiprole therapy
|
during and until 28 days after completion of ceftobiprole therapy
|
Assessement of Pseudomembranous colitis / Clostridium difficile colitis
Time Frame: during and until 28 days after completion of ceftobiprole therapy
|
during and until 28 days after completion of ceftobiprole therapy
|
Assessment of convulsions
Time Frame: during and until 28 days after completion of ceftobiprole therapy
|
during and until 28 days after completion of ceftobiprole therapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events by indication
Time Frame: during and until 28 days after completion of ceftobiprole therapy
|
during and until 28 days after completion of ceftobiprole therapy
|
Treatment dosage
Time Frame: During ceftobiprole therapy
|
During ceftobiprole therapy
|
Treatment duration in days
Time Frame: During ceftobiprole therapy
|
During ceftobiprole therapy
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Noëlle Jemmely, ADVANZ PHARMA Switzerland Sàrl
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Kidney Diseases
- Urologic Diseases
- Liver Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Liver Failure
- Hepatic Insufficiency
- Renal Insufficiency
- Anti-Infective Agents
- Anti-Bacterial Agents
- Ceftobiprole
- Ceftobiprole medocaril
Other Study ID Numbers
- BPR-PAS-001
- EUPAS30444 (Other Identifier: EU PAS Register)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Insufficiency
-
PfizerCompletedHealthy, Hepatic InsufficiencyUnited States
-
BeiGeneCompletedHepatic Insufficiency & Healthy SubjectsUnited States
-
BayerCompletedHepatic Insufficiency, Renal InsufficiencyGermany, Romania
-
Novartis PharmaceuticalsCompletedHepatic FailureUnited States
-
Cardiox CorporationTerminatedHepatic Failure
-
Centre Hospitalier Universitaire de NiceCompleted
-
Biotie Therapies Inc.Acorda TherapeuticsTerminatedHepatic ImpairmentUnited States
-
PfizerMedivation, Inc.Completed
-
Istituto Clinico HumanitasTerminatedIschemic Reperfusion Injury | Liver Tumour | Insufficiency; Hepatic, PostoperativeItaly
-
Assistance Publique - Hôpitaux de ParisUnknownFulminating Hepatic FailureFrance
Clinical Trials on Ceftobiprole medocaril
-
Basilea PharmaceuticaCompletedCommunity-acquired Pneumonia (CAP) | Hospital-acquired Pneumonia (HAP)Bulgaria, Hungary, Georgia, Romania
-
Basilea PharmaceuticaWithdrawn
-
Centre Hospitalier Universitaire DijonCompletedInflamed Meninges | Suspected Meningitis | VentriculitisFrance
-
Basilea PharmaceuticaCompletedAcute Bacterial Skin and Skin Structure InfectionsUnited States, Bulgaria, Hungary, Ukraine
-
Basilea PharmaceuticaCompletedDrug Resistance | Antimicrobial Agent | Cephalosporins
-
Basilea PharmaceuticaCompletedSkin Diseases, Infectious | Staphylococcal Skin Infections | Skin Diseases, Bacterial
-
Basilea PharmaceuticaCompletedICUUnited States, Belgium, Spain, Israel, Korea, Republic of, Canada
-
Basilea PharmaceuticaJohnson & Johnson Pharmaceutical Research & Development, L.L.C.CompletedStreptococcal Infections | Staphylococcal Skin Infections
-
Basilea PharmaceuticaCompletedTotal Hip Replacement Surgery
-
Basilea PharmaceuticaTerminatedNeutropenia | Fever | Gram-positive Bacterial Infections | Pseudomonas Infection